首页> 外文期刊>Clinical & developmental immunology. >Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
【24h】

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy

机译:肾切除术后肾细胞癌患者的自体CIK细胞免疫治疗

获取原文
           

摘要

Objective . To evaluate the efficacy of autologous cytokine-induced killer (CIK) cells in patients with renal cell carcinoma (RCC). Methods . 20 patients diagnosed with TNM stage I or II RCC were randomly divided into two groups, a CIK cell treatment group and a control group. The endpoint was progression-free survival (PFS) evaluated by Kaplan-Meier analyses. Results . CD3~(+), CD3~(+)/CD8~(+), CD3~(+)/CD4~(+), and CD3~(+)/CD56~(+)levels increased after CIK cell culture ( P < 0.01). The median PFS in CIK cell treatment group was significantly longer than that in control group (PFS, 32.2 months versus 21.6 months; log-rank, P = 0.032), all patients were alive during the course of followup, and there are no statistically significant differences between two groups in OS (log-rank, P = 0.214). Grade III or greater adverse events were not observed. Conclusions . CIK cells treatment could prolong survival in patients with RCC after radical nephrectomy and showed acceptable curative effect with potential enhancement of cellular immune function. This trial is registered with Clinicaltrials.gov NCT01799083 .
机译:目标。评估自体细胞因子诱导的杀伤(CIK)细胞在肾细胞癌(RCC)患者中的疗效。方法 。将20例诊断为TNM I或II期RCC的患者随机分为两组,即CIK细胞治疗组和对照组。终点是通过Kaplan-Meier分析评估的无进展生存期(PFS)。结果。 CIK细胞培养后CD3〜(+),CD3〜(+)/ CD8〜(+),CD3〜(+)/ CD4〜(+)和CD3〜(+)/ CD56〜(+)水平升高(P <0.01)。 CIK细胞治疗组的中位PFS显着长于对照组(PFS,32.2个月对21.6个月;对数秩,P = 0.032),所有患者在随访过程中均存活,并且无统计学意义OS中两组之间的差异(对数秩,P = 0.214)。未观察到III级或更严重的不良事件。结论。 CIK细胞治疗可延长根治性肾切除术后RCC患者的生存期,并显示出可接受的疗效,并可能增强细胞免疫功能。该试验已在Clinicaltrials.gov NCT01799083上注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号